Zealand Pharma AS (LTS:0NZU) Other Current Liabilities: kr280 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0NZU Zealand Pharma AS LTS:0NZU
41 GF Score
Price kr322.15
! 7 Warning Signs
View Full Analysis

What is Zealand Pharma AS Other Current Liabilities?

Zealand Pharma AS LTS:0NZU +1.16% 41 Other Current Liabilities is kr280 Mil as of Jun. 2026. GuruFocus rates LTS:0NZU with a GF Score™ of 41/100. The stock has 7 warning signs investors should review.

Zealand Pharma AS's other current liabilities for the quarter that ended in Jun. 2026 was kr280 Mil.

Zealand Pharma AS's quarterly other current liabilities declined from Dec. 2025 (kr269 Mil) to Mar. 2026 (kr201 Mil) but then increased from Mar. 2026 (kr201 Mil) to Jun. 2026 (kr280 Mil).

Zealand Pharma AS's annual other current liabilities increased from Dec. 2023 (kr85 Mil) to Dec. 2024 (kr167 Mil) and increased from Dec. 2024 (kr167 Mil) to Dec. 2025 (kr269 Mil).

Zealand Pharma AS Other Current Liabilities Related Terms

Zealand Pharma AS Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Other Current Liabilities Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.03 0.00 85.19 166.55 269.38

Zealand Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.88 121.14 269.38 201.00 280.00
LTS:0NZU
41GF Score
Zealand Pharma AS LTS:0NZU
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of kr280 Mil mean?
Zealand Pharma AS (LTS:0NZU) has a Other Current Liabilities of kr280 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zealand Pharma AS.
Is Zealand Pharma AS's Other Current Liabilities too high?
Zealand Pharma AS's current Other Current Liabilities is kr280 Mil. Overall, Zealand Pharma AS has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Other Current Liabilities compare to VRTX and REGN?
Zealand Pharma AS's Other Current Liabilities of kr280 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zealand Pharma AS. Zealand Pharma AS's current Other Current Liabilities is kr280 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (LTS:0NZU) has a current Other Current Liabilities of kr280 Mil. The current Other Current Liabilities is kr280 Mil. Zealand Pharma AS's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Zealand Pharma AS (LTS:0NZU), the current Other Current Liabilities is kr280 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
41GF Score

Get the complete analysis for LTS:0NZU

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr322.15
Price